Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
McKesson
Harvard Business School
Dow
AstraZeneca

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,759,059

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,759,059 protect, and when does it expire?

Patent 6,759,059 protects ABSTRAL and is included in one NDA.

This patent has thirty-five patent family members in twenty-four countries.

Summary for Patent: 6,759,059
Title: Fentanyl composition for the treatment of acute pain
Abstract:A pharmaceutical composition for the treatment of acute pain by sublingual administration is described. The composition comprises an essentially water-free, ordered mixture of fentanyl or a pharmaceutically acceptable salt thereof in the form of microparticles which are adhered to the surface of carrier particles which are substantially larger than the particles of fentanyl, and are essentially water-soluble. In a preferred embodiment, the composition also contains a bioadhesion and/or mucoadhesion promoting agent. The invention also relates to the preparation of the composition, and to the use of the composition for the treatment of acute pain.
Inventor(s): Pettersson; Anders (Kode, SE), Nystrom; Christer (Uppsala, SE), Lennernas; Hans (Uppsala, SE), Lennernas; Bo (Uddevalla, SE), Hedner; Thomas (Gallsta, SE)
Assignee: Diabact AB (Uppsala, SE)
Application Number:09/787,887
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,759,059
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 6,759,059

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sentynl Theraps Inc ABSTRAL fentanyl citrate TABLET;SUBLINGUAL 022510-001 Jan 7, 2011 AB RX Yes No   Start Trial   Start Trial Y MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER   Start Trial
Sentynl Theraps Inc ABSTRAL fentanyl citrate TABLET;SUBLINGUAL 022510-002 Jan 7, 2011 AB RX Yes No   Start Trial   Start Trial Y MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER   Start Trial
Sentynl Theraps Inc ABSTRAL fentanyl citrate TABLET;SUBLINGUAL 022510-003 Jan 7, 2011 AB RX Yes No   Start Trial   Start Trial Y MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER   Start Trial
Sentynl Theraps Inc ABSTRAL fentanyl citrate TABLET;SUBLINGUAL 022510-004 Jan 7, 2011 AB RX Yes Yes   Start Trial   Start Trial Y MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER   Start Trial
Sentynl Theraps Inc ABSTRAL fentanyl citrate TABLET;SUBLINGUAL 022510-005 Jan 7, 2011 AB RX Yes No   Start Trial   Start Trial Y MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER   Start Trial
Sentynl Theraps Inc ABSTRAL fentanyl citrate TABLET;SUBLINGUAL 022510-006 Jan 7, 2011 AB RX Yes No   Start Trial   Start Trial Y MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,759,059

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9803239Sep 24, 1998
PCT Information
PCT FiledSeptember 24, 1999PCT Application Number:PCT/SE99/01688
PCT Publication Date:March 30, 2000PCT Publication Number: WO00/16751

International Family Members for US Patent 6,759,059

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 247950   Start Trial
Australia 6492899   Start Trial
Australia 764473   Start Trial
Bulgaria 105380   Start Trial
Bulgaria 65363   Start Trial
Brazil 9913948   Start Trial
Canada 2345064   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Johnson and Johnson
Colorcon
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.